Share on StockTwits

Integra Lifesciences Holdings Corp (NASDAQ:IART) CAO John B. Henneman III sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $50.12, for a total value of $1,002,400.00. Following the transaction, the chief accounting officer now directly owns 34,159 shares in the company, valued at approximately $1,712,049. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up 0.18% on Tuesday, hitting $50.18. The stock had a trading volume of 172,201 shares. Integra Lifesciences Holdings Corp has a 52-week low of $37.92 and a 52-week high of $51.32. The stock has a 50-day moving average of $48.03 and a 200-day moving average of $46.63. The company’s market cap is $1.636 billion.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter last year, the company posted $0.60 earnings per share. Integra Lifesciences Holdings Corp’s revenue was up 12.6% compared to the same quarter last year. Analysts expect that Integra Lifesciences Holdings Corp will post $2.94 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Oppenheimer reiterated an “outperform” rating on shares of Integra Lifesciences Holdings Corp in a research note on Wednesday, August 6th. They now have a $57.00 price target on the stock, up previously from $55.00. Analysts at Jefferies Group raised their price target on shares of Integra Lifesciences Holdings Corp from $54.00 to $57.00 in a research note on Wednesday, August 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $52.57.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.